HZI - Helmholtz Centre for Infection Research
Analytics
- Ref-No. Technology
-
02-99999
Metax: Cross-Domain Metagenomic Profiling Technology
Animal Models
Bioinformatics
COVID-19 Related Technologies
Diagnostics
- Ref-No. Technology
-
02-00324
Innovative DOTA-Linkers for Bacterial Targeting
-
02-00351
Increased Availability and Efficacy of Aminoglycosides
-
02-00375
CRISPRdetect – multiplexed RNA detection with reprogrammed tracrRNAs
-
02-00396
Novel Lectin-Targeting therapeutics and diagnostics for Pseudomonas aeruginosa infections
-
02-00413
Rapid Detection of Shiga toxin producing E.coli (STEC)
-
02-00434
Programmable RNA-Guided Enzymes and Novel Orthogonal Substrates for Crispr Diagnostics
Drug Delivery
Gene Therapy
- Ref-No. Technology
-
02-00429
WarpDemuX - Method for Demultiplexing of RNA-sequencing DATA
Gene Therapy Tools
- Ref-No. Technology
-
02-00369
Biodynamers enhance drug delivery
Immunology/Autoimmune
- Ref-No. Technology
-
02-00374
Phytosphingosine Derivatives as Adjuvants in Immune Stimulation
Infectious Diseases
- Ref-No. Technology
-
02-00303
Novel Myxopyronin Analogues and Myxopyronin Genecluster for Mutasynthesis
-
02-00311
Cystobactamids – novel antibacterials against gram-negative pathogens
-
02-00324
Innovative DOTA-Linkers for Bacterial Targeting
-
02-00337
Novel Labyrinthopeptins as anti-viral agents
-
02-00351
Increased Availability and Efficacy of Aminoglycosides
-
02-00354
Highly active Chlorotonil A Derivatives for the treatment of Malaria
-
02-00372
Oral Antimotilin-Based Inhibitors for Treating Helicobacter pylori Infections
-
02-00373
First-in-Class S. aureus α-Hemolysin Inhibitors for Lung and Skin Infections
-
02-00374
Phytosphingosine Derivatives as Adjuvants in Immune Stimulation
-
02-00375
CRISPRdetect – multiplexed RNA detection with reprogrammed tracrRNAs
-
02-00376
Overcoming resistance - Innovative broad-spectrum inhibitors of Metallo- β-lactamases
-
02-00378
Best-In-Class P. aeruginosa LasB virulence factor Inhibitors
-
02-00387
Best-in-class Darobactin derivate against Gram-negative Bacteria
-
02-00396
Novel Lectin-Targeting therapeutics and diagnostics for Pseudomonas aeruginosa infections
-
02-00397
Novel vaccine vector platform for safe and effective immunization using a replication-deficient murine cytomegalovirus (MCMV)
-
02-00402
Novel inhibitors of Cytomegalovirus
-
02-00404
Inhibitors of Energy Coupling Factor (ECF) Transporters Against Gram-Positive Pathogens
-
02-00413
Rapid Detection of Shiga toxin producing E.coli (STEC)
-
02-00423
DeColi: Gut Decolonization of Multi-Resistant Escherichia coli
-
02-00432
Novel ASO-Based mRNA Silencing Technology for Phage-Host Interaction Research
Other Indications
Research Tools
Software
Therapeutics
- Ref-No. Technology
-
02-00311
Cystobactamids – novel antibacterials against gram-negative pathogens
-
02-00337
Novel Labyrinthopeptins as anti-viral agents
-
02-00351
Increased Availability and Efficacy of Aminoglycosides
-
02-00354
Highly active Chlorotonil A Derivatives for the treatment of Malaria
-
02-00369
Biodynamers enhance drug delivery
-
02-00372
Oral Antimotilin-Based Inhibitors for Treating Helicobacter pylori Infections
-
02-00373
First-in-Class S. aureus α-Hemolysin Inhibitors for Lung and Skin Infections
-
02-00376
Overcoming resistance - Innovative broad-spectrum inhibitors of Metallo- β-lactamases
-
02-00378
Best-In-Class P. aeruginosa LasB virulence factor Inhibitors
-
02-00385
Next-Generation Probiotics
-
02-00387
Best-in-class Darobactin derivate against Gram-negative Bacteria
-
02-00396
Novel Lectin-Targeting therapeutics and diagnostics for Pseudomonas aeruginosa infections
-
02-00397
Novel vaccine vector platform for safe and effective immunization using a replication-deficient murine cytomegalovirus (MCMV)
-
02-00402
Novel inhibitors of Cytomegalovirus
-
02-00404
Inhibitors of Energy Coupling Factor (ECF) Transporters Against Gram-Positive Pathogens
-
02-00415
Thiourea-Based Antibiotics against Acinetobacter baumannii
-
02-00423
DeColi: Gut Decolonization of Multi-Resistant Escherichia coli
-
02-00432
Novel ASO-Based mRNA Silencing Technology for Phage-Host Interaction Research
Vaccines
- Ref-No. Technology
-
02-00158
Cyclic di-Nucleotides as adjuvants
-
02-00361
Cyclic-di-AMP: a promising adjuvant for neonatal vaccines
-
02-00369
Biodynamers enhance drug delivery
-
02-00374
Phytosphingosine Derivatives as Adjuvants in Immune Stimulation
-
02-00397
Novel vaccine vector platform for safe and effective immunization using a replication-deficient murine cytomegalovirus (MCMV)
